Biogen Lifts Profit Guidance on Sales of Alzheimer’s Drug

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat Wall Street’s expectations.

Biogen now sees 2025 earnings per share of between $15.50 and $16, up from its previous forecast of between $14.50 and $15.50, the company said in a quarterly statement. It also projected that total revenue this year will be about flat compared to 2024, after previously projecting a mid-single digit decline.